GO
Loading...

FDA

More

  • FDA says Senomyx sweetener enhancer safe; shares jump Tuesday, 11 Mar 2014 | 10:55 AM ET

    March 11- Senomyx Inc said the U.S. health regulator designated its Sweetmyx food flavoring safe, paving the way for customers such as PepsiCo Inc to add it in drinks to reduce the use of sugar or sugar substitutes.

  • Some medical experts and lawmakers are urging the FDA to reconsider its approval of the new narcotic painkiller Zohyrdo, reports CNBC's Sheila Dharmarajan.

  • March 7- The U.S. Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday.

  • March 7- The U.S. Food and Drug Administration has asked Regeneron and Sanofi to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday. U.S.-listed shares of France- based Sanofi were down 1 percent.

  • March 6- Endo International Plc said the U.S. Food and Drug Administration approved its thrice-rejected testosterone replacement therapy, Aveed, to treat male hypogonadism.

  • FDA approves Endo Health's testosterone drug Thursday, 6 Mar 2014 | 7:14 AM ET

    March 6- Endo Health Solutions Inc said the U.S. Food and Drug Administration approved its thrice-rejected testosterone drug, Aveed, to treat male hypogonadism. The health regulator rejected the drug last May, saying that Endo needed a better plan to manage the risks associated with the drug.

  • March 4- Oxygen Biotherapeutics Inc said the U.S. Food and Drug Administration had lifted an order imposed in 2008 suspending trials of its experimental brain injury drug, sending the company's shares up by more than a third in early trading.

  • March 4- Oxygen Biotherapeutics Inc said the U.S. Food and Drug Administration had lifted an order imposed in 2008 suspending trials of its experimental brain injury drug, sending the company's shares up by more than a third in early trading.

  • March 4- Oxygen Biotherapeutics Inc said the U.S. Food and Drug Administration had lifted an order suspending trials of its experimental brain injury drug, sending the company's shares up by more than a third in premarket trading.

  • WASHINGTON, Feb 28- Generic drugmakers are furiously campaigning against a proposed U.S. rule that would require them to change the prescribing information on their products if they receive new safety information, which they say would open them to product liability lawsuits.

  • Feb 28- A new federal program aims to standardize inspection procedures for pet food and farm animal feed produced in the United States, making them safer, the U.S. Food and Drug Administration said on Friday.

  • John Foraker, Annie's CEO, discusses why its consumers are interested in non-GMO products. "Lowering our guidance had nothing to do with genetically modified ingredients," he explains.

  • Annie's CEO: Our anti-GMO edge     Friday, 28 Feb 2014 | 11:51 AM ET

    The Food and Drug Administration announced it wants to revamp nutrition labels on foods. John Foraker, Annie's CEO, discusses how a label change might impact his business.

  • The opioid drug, manufactured by Zogenix Inc, contains a potent amount of an active ingredient that could be lethal to new patients and children and is not safer than other current pain drugs, the groups told the Food and Drug Administration. In December, attorneys general from 28 states also urged the FDA to reconsider its approval of the drug.

  • Discussing the regulations for affordable medicine, with Mylan CEO Heather Bresch. She also discusses growth strategies for the company.

  • Food label makeover     Thursday, 27 Feb 2014 | 2:50 PM ET

    The White House and the U.S. Food and Drug Administration is proposing to change nutrition facts labeling. Meme Roth, National Action Against Obesity president, and Katherine Mangu-Ward, Reason Magazine managing editor, share their opinions.

  • Groups urge FDA to halt launch of Zohydro pain drug Thursday, 27 Feb 2014 | 12:42 PM ET

    The opioid drug, manufactured by Zogenix Inc, contains a potent amount of an active ingredient that could be lethal to new patients and children and is not safer than other current pain drugs, the groups told the Food and Drug Administration. In December, attorneys general from 28 states also urged the FDA to reconsider its approval of the drug.

  • Feb 25- Anika Therapeutics Inc said the U.S. Food and Drug Administration approved its drug to treat pain and improve joint mobility in patients with osteoarthritis of the knee, more than four years after it first filed for approval.

  • FDA approves Anika Therapeutics arthritis drug Tuesday, 25 Feb 2014 | 4:24 PM ET

    Feb 25- Anika Therapeutics Inc said the U.S. Food and Drug Administration approved its drug to treat pain and improve joint mobility in patients with osteoarthritis of the knee. The company said the drug will be marketed in the United States by Depuy Synthes, a unit of Johnson& Johnson.

  • Feb 25- Bristol-Myers Squibb Co said the U.S. Food and Drug Administration approved its drug to treat rare and potentially fatal disorders involving loss of body fat. Bristol-Myers said the FDA had asked it to conduct seven post-marketing studies on Myalept. The drugmaker had co-developed the drug with AstraZeneca.

Most Popular Video

Tuesday, 15 Apr 2014 | 6:00 PM ET

Fear and loathing. Mad Money host Jim Cramer looks at fears professional money managers face in the current market environment.

Tuesday, 15 Apr 2014 | 4:00 PM ET

CNBC's Patti Domm sits down with Lindsey Group Chief Market Analyst Peter Boockvar to discuss whether or not inflation could affect the Fed's plans.

Tuesday, 15 Apr 2014 | 3:00 PM ET

CNBC.com Senior Writer John Jannarone talks about what Coca-Cola really needs to do to sustain revenue growth.